6 results about "Infection types" patented technology

The invention provides a kit and a method for identifying the infection category of a sample to be detected by detecting host peripheral blood gene expression, the kit simultaneously detects expression levels of two groups of genes in the sample to be detected, the first group is genes for identifying bacterial infection, the group of genes are S100P gene, ANXA3 gene, ITGAX gene and ITGAM gene, and the group of genes are S100P gene, ANXA3 gene, ITGAX gene and ITGAM gene. The first group is a gene for identifying fungal infection, the second group is a gene for identifying fungal infection, the group comprises an IFI44L gene, an IFIT3 gene, an IFIH1 gene, an LY6E gene, an IFIT1 gene and an IFITM3 gene, and whether the sample to be detected is bacterial infection, fungal infection, simultaneous bacterial and fungal infection or non-bacterial and non-fungal infection is determined by detecting the two groups of genes. According to the invention, ten genes expressed in peripheral blood are screened out, so that the detection cost and accuracy for distinguishing bacterial infection and virus infection can be kept at a balance point, and finally, clinical application can be realized.

This invention belongs to the field of biological detection technology, and particularly relates to a reproductive tract HPV-mRNA-E6 / E7 detection system and method based on nanopore sequencing. The system includes a sample pretreatment module, an RNA extraction and purification module, a reverse transcription module, a nanopore sequencing module, and a bioinformatics analysis module. The method includes the following steps: (1) reproductive tract sample collection and pretreatment; (2) extraction and purification of HPV-mRNA in the sample; (3) reverse transcription of the purified HPV-mRNA into cDNA; (4) nanopore sequencing of the cDNA to obtain raw sequencing data; (5) filtering, comparing, and annotating the sequencing data through the bioinformatics analysis module to achieve HPV type identification and quantitative analysis of E6 / E7 gene expression levels. This invention utilizes the advantages of nanopore sequencing, such as long read length and real-time detection, combined with the specificity of E6 / E7 mRNA as a biomarker of active infection. It can directly detect latent and active HPV infection, improve detection sensitivity, accurately distinguish infection types, and shorten the detection cycle. It enables rapid, accurate, and high-throughput detection of active HPV infection in the genital tract, providing reliable technical support for early screening, disease monitoring, and prognostic assessment of HPV-related diseases such as cervical cancer.

The invention provides an infectious fever antibacterial scheme selection method and system based on multi-dimensional data, and belongs to the technical field of infectious disease diagnosis and treatment. The method comprises the following steps: step (1), identifying a fever type based on symptom and sign data and inspection data, and positioning a pathogen type, an infection site and severity; (2) generating candidate antibiotic schemes based on the antibiotic knowledge base and a guide rule engine; (3) adjusting the dosage according to the individual parameters of the patient, and generating a first scheme and an alternative scheme; through multi-dimensional data integration, infection types are rapidly identified, antibiotics recommended by a guide are matched, and an accurate and safe antibacterial scheme (including a first scheme and an alternative scheme) is generated according to individual conditions of patients.

The application belongs to the field of biological detection, and particularly relates to sgRNA and RPA primer group, a detection system and application for synchronous detection of four pig-derived viruses. The sgRNA and RPA primer group for synchronous detection of four pig-derived viruses comprises sgRNA and RPA primer group for detecting porcine acute diarrhea syndrome coronavirus, porcine rotavirus, porcine transmissible gastroenteritis virus and porcine epidemic diarrhea virus. The application further provides a centrifugal microfluidic chip for synchronous detection of four pig-derived viruses, which can be used to synchronously and highly specifically identify multiple pig-derived viruses and accurately distinguish infection types in a single detection process, and the detection result has both laboratory-level sensitivity and accuracy.

This invention provides a kit and method for identifying the infection type of a test sample by detecting gene expression in host peripheral blood. The kit simultaneously detects the expression levels of two groups of genes in the test sample. The first group consists of genes for identifying bacterial infection, including the S100P, ANXA3, ITGAX, and ITGAM genes. The second group consists of genes for identifying viral infection, including the IFI44L, IFIT3, IFIH1, LY6E, IFIT1, and IFITM3 genes. Detection of these two groups of genes determines whether the test sample is infected with bacteria, virus, a combination of bacteria and virus, or neither bacteria nor virus. This invention screens out 10 genes expressed in peripheral blood, achieving a balance between the cost and accuracy of distinguishing between bacterial and viral infections, ultimately enabling clinical application.

A computer-implemented method determines an optimal drug dosing regimen to treat a patient against a drug-sensitive pathogenic agent responsible for infection. The method obtains patient data and drug data, including the drug, administration route, adaptation type (priori or posteriori), and a drug treatment regimen. The method includes determining values for pharmacokinetic parameters for efficacy (PPE) and pharmacokinetic parameters for toxicity (PPT) from the patient and drug data using population pharmacokinetic models when PPE and PPT are not obtained directly from measurement concentration(s). The method includes obtaining infection data, including parameters selected from the documentation of infection, localization, infection type, identified pathogen, susceptibility, and minimum inhibitory concentration. The method includes determining an efficacy target for the drug from the infection data and a target at risk of toxicity. The method includes determining an optimal dosing regimen by comparing PPE with the efficacy target and PPT with the risk of toxicity target.